Applications for next MSc PoP granting round being accepted until February 25, 2016
TORONTO (January 26, 2016) — Nine Ontario-based medical research projects built on great science with potential for significant economic impact are advancing a step closer to market entry thanks to funding from Ontario Centres of Excellence’s Medical Sciences Proof-of-Principle (MSc PoP) program. The projects range from cancer to heart disease to sleep apnea in children.
Applications for the next MSc PoP granting round are open until March 4, 2016. To ...
Partners for JLABS @ Toronto include Janssen Inc., MaRS Innovation and seven of MI's 15 member institutions
TORONTO, Sept. 8, 2015 — The Ontario Government, University of Toronto, and MaRS Discovery District (MaRS) today announced a collaboration with Janssen Inc. to launch the successful Johnson & Johnson Innovation, JLABS incubator model in Toronto.
This announcement has been covered in the Toronto Star, Metro News Canada, Sing Tao Daily, OurWindsor.ca, FierceBiotech, BioCentury, MedCity News, BioSpace, Biotechnology Focus, Lab Product News, ChinaNews.com, Pan European Networks, Economic ...
BresoTec, formerly known as ApneaDx, also among top five finalists
TORONTO, August 11, 2015 – Legworks' next-generation prosthetic knee took first place in Ontario Centres of Excellence’s (OCE’s) Parapan Am Games-affiliated Accessibility Tech Pitch competition. The company immediately said it would use the $20,000 award to fit 200 amputees in developing countries with its device.
Legworks was selected from 18 participants in a two-day elimination pitch competition – one of the features of the Government of Ontario’s Accessibility Innovation Showcase held at MaRS ...
MaRS Innovation today announced that Johnson & Johnson Innovation has expanded its collaboration with MaRS Innovation to identify and advance early-stage technologies of interest.
The announcement was made in advance of the 2015 BIO Convention, which takes place from June 15 to 18 in Philadelphia, PA. MaRS Innovation is participating as part of the Ontario delegation and will have kiosk space in the Ontario pavilion (#615).
This partnership was covered in BioCentury, GEN, PharmaBiz and FierceBiotech.
Earlier this year, Johnson & Johnson Innovation and ...
TORONTO, Sept. 29, 2014 — AvidBiologics Inc., an oncology drug development company, today announced the closing of a financing round. The company is founded on antibody-drug conjugate (ADC) technologies co-developed with the National Research Council of Canada (NRC).
Led by Lumira Capital, the financing round included MaRS Innovation (MI), MaRS Investment Accelerator Fund (IAF), Rosseau Asset Management, and the company's founding investors.
This announcement was covered by Dow Jones: Private Equity and Venture Capital and by Canadian Private Equity.
Today's financing builds on prior ...
Technology developed by Dr. Stuart Berger at UHN is first project funded through partnership
TORONTO, Dec. 11, 2013 - MaRS Innovation, a Centre of Excellence for Commercialization and Research, has announced the first project funded through the Pfizer Inc. and MaRS Innovation strategic partnership.
Dr. Stuart Berger, senior scientist at University Health Network, has developed a potential innovation for the bio-manufacturing sector, which is a rapid-growth area.
This announcement was covered by BetaKit.
His technology generates cell lines with improved protein production and survival properties, important in the ...
Council members include MI’s Raphael Hofstein and MI Board Chair Dr. Robert Bell
On November 20, the Government of Ontario launched the Ontario Health Innovation Council to support health innovation in Ontario. Dr. Raphael Hofstein, president and CEO of MaRS Innovation, was named to the council.
By becoming a member of the Council, Hofstein will assist in identifying evidence-based opportunities in Ontario’s healthcare space and advancing them into practice on a global scale. (more…)
In a November 25 article in Biotechnology Focus magazine, author Shawn Lawrence highlights Stem Cell Therapeutics and Trillium Therapeutics Inc. coming together in a reverse merger that creates more opportunities to advance early-stage research.
The article profiles Dr. Aaron Schimmer and his discovery that Tigecycline is effective in killing leukemia cells and leukemia stem cells by shutting down their energy supply.
Here's a quote from Lawrence's article:
“Dr. Schimmer’s research is focused on drug repurposing – finding new indications for approved therapeutics. Focusing on established drugs ...
Thotra's speech transformation technology to improve comprehension in call centres and transcription services worldwide
On October 11, 2013, The Hindustan Times covered a technology developed by UTEST start-up graduate Thotra (invented by Frank Rudzicz) for its speech-transformation software.
The article commends Thotra for recognizing the communications gap surrounding accents, hailing the technology as the solution to "put an end to all accent problems."
On October 2, 2013, Thotra's technology was also covered in the National Post:
The software, which filters out aspects of speech that ...
Four University of Toronto (U of T) professors who have commercialization projects in various stages with MaRS Innovation were named to the university's list of Inventors of the Year.
“The Inventor of the Year Award is meant to recognize inventions that have the potential to improve our quality of life,” said Professor Paul Young, vice-president (research and innovation) and a member of MaRS Innovation's Board of Directors. “The winning inventions represent the very best of innovation at U of T, and on ...